Did you miss our webinar, 'Improve Oncology Clinical Trial Readiness for Faster Proof-of-Concept,' presented by Luke Gill, Vice President and Global Head of Oncology and Medical Affairs, and Yong Wang, Head of Biometrics? Its now available on demand – bit.ly/3S4oSdS • Bayesian Designs: Replaces rigid 3 3 rules with flexible models (like BOIN) to find optimal benefit-risk doses instead of just maximum tolerated doses. • Master Protocols: Uses basket, umbrella, and platform structures to run multiple biomarker-driven sub-studies under one overarching infrastructure. • Real-World Evidence (RWE): Employs external control arms and hybrid models to supplement trial data for rare diseases and fast-track approvals. • Global Regulatory Agility: Accelerates early execution in Australia, builds FDA credibility, and integrates China into early Phase I/II proof-of-concept. #BayesianDesigns #MasterProtocols #RWE #Global Regulatory Agility #PoC

Master protocol designs provide clear advantages – speed, efficiency, and flexibility – yet they also involve additional considerations. 🧪⚖️ Curious about the opportunities? Check out our infographic to learn how these innovative trial designs are reshaping clinical research. #ClinicalTrials #MasterProtocols #Innovation

Ever heard of master protocols? 🔬💡 These innovative clinical trial designs - platform, basket, and umbrella trials - help speed up research by testing multiple treatments or conditions under one framework. Check out the infographic to see how each type works and why they’re shaping the future of #ClinicalTrials! To learn more, check out our white paper 📄 - Revolutionizing clinical trials: How master protocols and adaptive platform trials are changing drug development: gcaresearch.org/educational-… #ClinicalResearch #MasterProtocols #PlatformTrials #BasketTrials #UmbrellaTrials

Today, on #GBMDay, we stand with everyone affected by #glioblastoma – the most aggressive and deadliest form of brain cancer, with a median survival of just 9 months and a 5-year survival rate of only 7.1%. GCAR is proud to lead #GBMAGILE, an innovative global trial accelerating access to potential therapies. Since 2019, we've screened over 2,300 patients and expanded to sites across North America, Europe and Australia. This progress is only possible because of the tireless efforts of participants, caregivers, researchers, and partners around the world. Your commitment fuels hope and brings us closer to better outcomes. Thank you! Additional thanks to our pharmaceutical partners: @Bayer , @Kintara_Thera, @KaziaTx, @biohaven , @vigeotx , Polaris Pharmaceuticals, and @AstraZeneca And to our vendors and advocacy partners: @NBTStweets, @braincancer_AU, @NFCR , AFCR, @BerryConsultant, @IQVIA_Biotech, @wilsonsonsini, and @Medidata #GBM #ClinicalTrial #ClinicalResearch #FasterTogether #PlatformTrials #MasterProtocols

Be the first to know what’s next at GCAR! Subscribe to GCAR’s newsletter for exclusive updates on our cutting-edge platform trials, research initiatives, and the latest developments – delivered straight to your inbox. Join a global community of researchers, clinicians, patients, and advocates driving progress for patients. We are #FasterTogether. To join the mailing list, please visit: gcaresearch.org #PlatformTrials #MasterProtocols #Newsletter #ClinicalResearch #ClinicalTrials

New White Paper! INNOVATION IN ACTION: Data Management Strategies for Master Protocols and Adaptive Platform Trials is here! 📄💡 Master protocols are transforming clinical trials - evaluating multiple therapies under one adaptable framework for faster results, lower costs, and reduced patient burden. At the core of this innovation is the growing priority to build data management systems that are strong, secure, and scalable. 🔐📊 In this white paper, GCAR explores: ✅ Key infrastructure considerations ✅ Data maintenance and locking best practices ✅ Sponsor oversight in data management ✅ Blinding and masking considerations ✅ Integrating artificial intelligence and machine learning 📥 Download now and see how GCAR is setting the standard for data integrity in next-generation clinical research: gcaresearch.org/educational-… #ClinicalTrials #DataManagement #AdaptiveTrials #MasterProtocols #ClinicalResearchInnovation #AIinHealthcare #GCAR #WhitePaper

We've now got a full agenda for the day! REGISTER TODAY to secure yourself a spot for in-person or online attandence: store.bath.ac.uk/conferences… #statistics #clinicaltrials #adaptivedesigns #masterprotocols #sequential #decisionmaking

We're thrilled to share valuable insights and actionable solutions with our latest white papers! 📄✨ Our first two papers dive into master protocols, highlighting benefits to stakeholders and key operational considerations for these specialized trials. Stay tuned – we’ll be releasing more white papers in the coming months, covering topics like site activation & engagement, data management, financial efficiency, and resourcing. We are eager to continue to educate and raise awareness about these innovative clinical trial solutions, with the goal of elevating and engaging the broader community. We are #FasterTogether! To read our latest white papers, visit: gcaresearch.org/educational-… #ClinicalTrials #MasterProtocols #Innovation #WhitePapers #ClinicalResearch

Always exciting to talk about #PrecisionMedicine trials and how to make them efficient using innovative designs, and efficient statistical methods. Work 2G with @JMSWason @haiyan_zheng #BasketTrials #umbrellaTrials #MasterProtocols @nclBiostats

Our latest paper with @JMSWason @haiyan_zheng, NW & MJG in @FrontMedicine reviews stats considerations for the design & analysis of umbrella trials so far, paying attention to non-oncology settings. Novel stats methods needed @nclBiostats #Masterprotocols doi.org/10.3389/fmed.2022.10…

Hear from our experts at #WVCDC on Wednesday, 20 April! 𝟭𝟭:𝟰𝟬 𝗮.𝗺. 𝗘𝗧: Cyrille Bonhomme on #vaccineefficacy 𝟭𝟮:𝟭𝟬 𝗽.𝗺. 𝗘𝗧: Anusha Streubel and Trang Grisler on #masterprotocols If you have any post-session questions, our team would love to chat at booth 400!

DIA 2021 Annual Meeting: #FDA Flags #MasterProtocols, #DecentralizedTrials as Focal Points. #ClinicalTrials #ClinicalResearch #Covid-19 #Technology buff.ly/3khX5DP @FCR_News_Today

Need cancer drug development guidance? Check out 7 #FDAOncology guidances posted so far this year. #clinicaltrials #cnsmets #breastcancer #masterprotocols #pediatriconcology bit.ly/3dOXrxA

2nd day into @imi_eupearl 3rd GAM.🎯Today diving into #masterprotocols📰 and the role of federated networks to optimize IRP designs. More on how this @IMI_JU project plans to transform #clinicaltrials here ⏩eu-pearl.eu #innovation #platformtrial #EUPEARL_GAM3

Use of #MasterProtocols Expected to Grow in Wake of #FDA Guidance. #ClinicalTrials #ClinicalResearch #Covid-19 #WCG buff.ly/3wGXi6p @FCR_News_Today

Don't miss this interesting talk by @posch_m today at #DIA forum about #masterprotocols in the COVID-19 pandemic and beyond. Discover how @imi_eupearl is contributing to address methodological challenges and bring innovation to #clinicaltrials. @IMI_JU bit.ly/2PUeSEk

We lack a centralized and coordinated approach for clinical trials (ex: #masterprotocols), instead left with an entrepreneurial landscape of incremental and underpowered studies that may boost some academic egos but do little for research participants or patients.

The world owes thanks to the #masterprotocols from WHO. Big kudos to @derkarts and the team at @CastorEDC for providing the research technology that supported this vital research.

.@DrWoodcockFDA Operation WarpSpeed presenting @CTTI_Trials public summit on advancing #masterprotocols – fastest path to effective #COVID19 treatments Dr. Derek Angus of @UPMC presenting on @remap_cap among other panelists

#MasterProtocols can provide opportunities for flexibility in the highly regulated #clinicaldevelopment industry which needs to operate with safety. Read the article to know about the types of designs in Master Protocols for #ClinicalTrials #Veeda #BasketTrials #UmbrellaTrials